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eativecommons.org/licenses/by-nc-Summary Objective: To compare the effectiveness of early termination (ET) and standard
termination (ST) of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) using
internally cooled electrodes.
Methods: Eighty-three treatment naı¨ve patients with HCC with 101 index tumor under-
went RFA. ET was defined as termination of ablation if after 6 minutes the power emis-
sion was < 10 seconds for three times per minute under maximal power. Standard
termination was defined as termination of ablation according to manufactures’ algorithms
of 12 minutes’ procedure. Primary end point was complete ablation of index tumor after
4 weeks of RFA.
Results: Nineteen patients (22.9%) underwent ET and 64 patients (77.1%) underwent ST.
The mean size of the index tumor was 2.2 þ 0.9 cm. Patient had complete ablation of
the index tumor at 92.0% for the ET and 88.2% for the ST (p Z 0.593). Eight of 25
(32.0%) for the ET and 18 of 73 (24.7%) for the ST group had local tumor progression
on last follow-up (p Z 0.473). After a median follow-up of 23 weeks (range, 9e33Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung
rsity Number 5, Fu Hsing Street, Kuei Shan, Taoyuan 333, Taiwan.
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168 Y.-T. Cheng et al.weeks), the 24 weeks cumulative probability of local tumor progression was not different
between ET (46.2%) and ST (25.6%; p Z 0.387). Complete ablation at 4 weeks was the
only independent factor associated with local tumor progression (adjusted hazard ratio
0.04, 95% confidence interval 0.01e0.16, p < 0.001).
Conclusion: Using ET in RFA is as effective as the ST in achieving complete ablation and
local tumor progression.
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Hepatic resection and transplantation are the potential
curative therapy for hepatocellular carcinoma (HCC). Un-
fortunately, only 20e30% of those patients presenting with
HCC are eligible candidates [1,2]. With the introduction of
radiofrequency ablation (RFA) in 1983, it has become one of
the modalities that have been gaining acceptance in
treating small inoperable HCC [3e12]. RFA have been
shown in several studies to have a high complete ablation
rate of 85e96% in the management of HCC < 5 cm in
diameter [4e11].
The mechanism behind RFA is based on adequate
conversion of electrical energy to thermal energy to
produce tissue heating. The heat has coagulation and
direct cytotoxic effects on the tumor leading to tumor
destruction [12]. Several electrodes are available
commercially and the internally cooled electrode is
among the commonly used electrode because of its ease
of use and proven efficacy [3e16]. Its tip is internally
cooled to prevent tissue charring leading to a significant
increase in energy delivery and lesion size [13e16]. Pre-
vious studies showed that increasing the power or pro-
longed ablation procedure would produce larger
coagulation area however a power > 130 watts would
induce a frequent increase in impedance and multiple
automatic reduction in current that might consequently
diminish the total treated time [14e18]. A rising imped-
ance may be due to irreversible dehydration and charring
[19,20] or due to reversible formation of electrically
insulating gas between the electrode and the tissue due
to boiling and evaporation of tissue fluid [21].
Modification of treatment strategies such as performing
percutaneous saline-enhanced impedance controlled RFA
to minimize potential carbonization to produce a larger
tumor response rate has been studied; though promising, it
is not often convenient and applicable to all operators
[21,22]. Hence seeking for newer techniques, constant
modification or refinement of treatment strategies is of
value.
This study aimed to determine whether there is any
difference in using the early termination technique than
the standard termination in terms of complete ablation of
the index tumor, local tumor progression, and complication
rates.Methods
Patients
Consecutively registered patients with HCC who underwent
RFA using internally cooled electrode from May 2010 to
April 2011 at Chang Gung Memorial Hospital (Linkou
Branch), Taipei, Taiwan were screened. The study included
patients with treatment-naı¨ve HCC with less than three
index tumors and < 4 cm in size. Excluded patients were
those with Child-Pugh Class C cirrhosis, with macroscopic
vascular invasion or extrahepatic metastases and those
with malignancy other than HCC.
The diagnosis of HCC was through cytologic or histo-
pathologic findings or the presence of a hypervascular liver
mass in the arterial phase of a dynamic imaging study
(computed tomography or magnetic resonance imaging)
with contrast washout during the portal or delayed phase
plus angiographic confirmation of a hypervascular mass or
an a-fetoprotein concentration > 200 ng/mL. Patient de-
mographics, hematology, biochemistry, size, and number of
index tumor were recorded. Etiological factors of hepatitis
B virus or hepatitis C virus were examined by serological
assays. Patients included in the study gave informed writ-
ten consent for RFA.Radiofrequency ablation technique
This study was limited to patients treated with an internally
cooled electrode with a 3-cm uninsulated tip (Cool-tip
radiofrequency system, Valleylab Inc., Boulder, CO, USA) in
all tumors. Cluster-type electrodes were not used in this
study. All RFA were performed by three gastroenterologists
with at least 10 years’ experience with sonographic-guided
interventions. Multiple overlapping ablations were per-
formed as needed to cover the whole tumor plus a 5- to 10-
mm ablative margin around the tumor, when feasible
[3,12,17,18]. Electrode track thermocoagulation was
routinely performed with a temperature over 70C on
withdrawal [3,12,17,18,23].
A standard protocol for conscious sedation consisting of
30 mg meperidine and 3 mg midazolam were administered
intravenously prior to ablation. These doses were then
titrated to achieve an adequate comfort level throughout
115 paƟents undergoing 1 Ɵme 
radiofrequency ablaƟon using cool Ɵp 
Excluded: 18-previous TACE 
1- Child C 
6- > 3 tumors 
4- tumor size > 4 cm 
86 paƟents included
83 paƟents final analysis 
3- lost at follow-up 
19 paƟents early terminaƟon 64 paƟents standard terminaƟon
Figure 1 Flowchart of patient distribution. TACE Z trans-
arterial chemoembolization.
RFA of HCC: Early versus standard termination 169the procedure. Continuous monitoring of vital signs and
oxygen saturation during the procedure was performed.
Local anesthesia with 1% lidocaine hydrochloride was
applied along the planned puncture site. The electrode was
introduced percutaneously through the tumor for at least
0.5 cm beyond its deep margin under real-time sonographic
guidance (Aplio SSA-700A, Toshiba, Tokyo, Japan). The
radiofrequency generator contains an internal program that
automatically runs a 12-min pulsed energy ablation cycle
and adjusts the power output relative to tissue impedance
to optimize the diameter of ablated tissue.
For the early termination group (ET) maximum power
setting was done and if after 6 minutes the power emission
was < 10 seconds for three times per minute the ablation
was terminated after 9 minutes. As for the standard
termination (ST) the modified automated algorithm as
previously described was used [18]. Briefly, the ablation
begins by activating the impedance control mode with a
gradual increase in power output over the 1st minute to
reach 120 W. The power is maintained at this level until
tissue impedance rises to 20 U above the baseline imped-
ance. The power output is automatically reduced to zero
for 15 seconds once the 20 U of threshold is exceeded. The
power is then returned to the initial peak power setting
until the tissue impedance rises again. Successive cycles
are continued for 12 minutes to complete a single ablation.
The discretion to perform either technique was left to the
decision of the operator.
Follow-up protocol
Four weeks after the ablation, a dynamic imaging study
[computed tomography (CT) or magnetic resonance imaging
(MRI)] was performed to assess the completeness of abla-
tion. A completely ablated tumor was defined as an area of
low attenuation on CT or low signal intensity on T2-
weighted MRI that encompassed the area of the index
tumor with no nodular peripheral enhancement on dynamic
studies [23]. Any nodular enhancement seen in the treated
tumor was considered to be a residual viable tumor. In
cases of incomplete ablation, additional sessions using the
same algorithm or percutaneous ethanol injection or
transarterial chemoembolization (TACE) were performed.
Treatment for each tumor is limited to three sessions within
3 months. An immediate follow-up dynamic study was
carried out to confirm the absence of a residual tumor after
the additional treatments. After complete ablation, moni-
toring for local recurrence with dynamic imaging studies,
liver function tests, and a-fetoprotein measurement were
done every 3e6 months.
Study endpoints
The primary endpoint of this study was complete ablation
of the index tumor after one RFA session. Secondary end
points were primary effectiveness defined as complete
ablation of the index tumor after more than one RFA session
and local tumor progression. Local tumor progression was
defined as the appearance of nodular enhancement
contiguous with the ablated tumor on dynamic study or an
increase in the size of the ablated area on follow-upimaging of a tumor that was previously completely ablated
[23]. Major complications were defined as those requiring
therapy with hospitalization or involving permanent
adverse sequelae. These endpoints were based on the
guidelines set by the International Working Group on Image-
Guided Tumor Ablation [23].
Statistical analysis
Statistical analysis was performed using IBM SPSS statistics
for Windows version 19.0 (Armonk, NY, USA). Continuous
variables were presented as mean  standard deviation or
median (interquartile range), and compared using un-
paired t test or ManneWhitney U test as appropriate.
Categorical variables were presented as frequency (per-
centage) and compared using the Chi-square test or
Fisher’s exact test as appropriate. Cumulative probability
local tumor progression was estimated with KaplaneMeier
curve. Multiple logistic regression analysis was used to
determine independent predictors of complete ablation
and Cox regression analysis with forward logistic regres-
sion was used to model independent predictors of local
tumor progression. Covariates with p < 0.05 from univar-
iate analysis were included in multivariate analysis. All
statistical tests were two sided and a p < 0.05 was
considered statistically significant. Survival analysis was
not performed due to the short-term follow-up of the
study population.
Results
Patients characteristics
A total of 115 patients underwent first-time RFA using
internally cooled electrode during the study period.
170 Y.-T. Cheng et al.Twenty-nine patients were excluded due to history of
previous treatment (n Z 18), Child-Pugh class C (n Z 1),
index tumor number of more than three (n Z 6) and
tumor size of more than four (n Z 4). Eighty-three pa-
tients were eventually included in the final analysis, with
19 patients belonging to the ET group and 64 patients to
the ST group (Figure 1). The mean age of patients was
67.0 þ 9.2 with a median follow-up of 23 weeks (range,
9e33 weeks). The mean size of the index tumor was
2.2 þ 0.9 cm. More cirrhotic patients (89.1%) were
included in the ST group than ET group (68.4%, pZ 0.030;
Table 1).
Complete ablation
A total of 101 index tumors were included in the analysis for
complete ablation after 4 weeks of RFA with 25 tumors for
the ET group and 76 tumors for the ST group. There was no
significant difference between the 92% of the ET group and
88.2% of the ST group in achieving complete ablation after 4
weeks of RFA (p Z 0.593). There was also no significant
independent factor, including a tumor in a difficult-to-treat
location, that would predict complete ablation after 4
weeks of RFA from our study (Table 2).Table 1 Clinical characteristics of patients and outcome mana
Characteristics All (n Z 83)
Age (y) 67.0 þ 9.2
Male (%) 55 (66.3)
Etiologic factor
Hepatitis B virus 25 (30.1)
Hepatitis C virus 40 (48.2)
Othersa 18 (21.7)
Cirrhosis 70 (84.3)
Child-Pugh class (n Z 70)
A 50 (71.4)
B 20 (28.6)
a-fetoprotein (ng/mL) 9.7 (4.8e36.7)
Total bilirubin (mg/dL) 0.9 þ 0.6
Albumin (g/dL) (n Z 80) 3.6 þ 0.6
Prothrombin time (international
normalized ratio)
1.2 þ 0.1
Platelet count (109/L) 115.6 þ 53.6
Size of index tumor (cm) (n Z 101) 2.2 þ 0.9
Single tumor 65 (78.3)
No. of index tumor 1.2 þ 0.4
Patients with tumors in difficult-to-treat
location
24 (28.9)
Cool down temperature (C) (n Z 81) 65.3 þ 7.6
Complete ablation at 4 wk (n Z 101) 90 (89.1)
Primary technique effectiveness (n Z 101) 98 (97)
Local progression (n Z 98)b 21 (21.4)
New HCC on follow-up (n Z 98)b 5 (5.1)
Data are presented as n (%), mean þ standard deviation, or median (
a Alcoholic liver disease (n Z 6), idiopathic (n Z 5), hepatitis B an
cirrhosis (n Z 1), hepatitis B and alcoholic liver disease (n Z 2).
b Not included in analysis because dynamic images after complet
achieved (n Z 1).Primary technique effectiveness
Among the 11 tumors not completely ablated after one RFA
session, eight were managed with further RFA session to
achieve complete ablation. Of the remaining three tumors
with incomplete ablation, two underwent transarterial
chemoembolization and one underwent ethanol injection
that was determined by patient’s preference. All patients
in the ET group and 73 in the ST group (96.1%) achieved
primary technique effectiveness (p Z 0.313).
Local tumor progression
Out of the 101 tumors, only 98 tumors were included in the
final analysis for local tumor progression because dynamic
images after complete ablation were unavailable for two
tumors and complete ablation was not achieved in one
tumor. The follow up duration was 20.1 þ 14.8 weeks
(20.2 þ 13.1 weeks for the ET group and 20.0 þ 15.4 weeks
for the ST group; pZ 0.966). Twenty-one tumors had local
recurrence and five tumors were new recurrences. Local
tumor progression for the ET group and ST group were not
significantly different (32% and 24.7% respectively,
p Z 0.473). Both cirrhosis and complete ablation after 4gement of hepatocellular carcinoma for patient groups.
Early Termination
(n Z 19)
Standard Termination
(n Z 64)
p
66.7 þ 9.9 67.1 þ 9.1 0.896
15 (78.9) 40 (62.5) 0.183
0.560
4 (21.1) 21 (32.8)
11 (57.8) 29 (45.3)
4 (21.1) 14 (21.9)
13 (68.4) 57(89.1) 0.030
0.627
10 (76.9) 40 (70.2)
3 (23.1) 17 (29.8)
12.3 (5.7e39.6) 8.1 (4.2e36.0) 0.319
1.0 þ 0.6 0.9 þ 0.6 0.428
3.7 þ 0.7 3.6 þ 0.6 0.439
1.2 þ 0.2 1.2 þ 0.1 0.342
112.0 þ 55.6 116.6 þ 53.4 0.743
2.1 þ 0.8 2.3 þ 1.0 0.271
13 (20) 52 (80) 0.216
1.3 þ 0.5 1.2 þ 0.4 0.239
6 (31.5) 18 (28.1) 0.538
62.4 þ 7.8 66.2 þ 7.4 0.057
23/25 (92) 67/76 (88.2) 0.593
25/25 (100) 73/76 (96.1) 0.313
6/25 (24) 15/73 (20.5) 0.717
2/25(8) 3/73 (4.1) 0.445
interquartile range) as appropriate.
d C coinfection (n Z 3), Wilsons disease (n Z 1), primary biliary
e ablation unavailable (n Z 2) and complete ablation was not
Table 2 Factors predicting complete ablation after 4 weeks of radiofrequency ablation among hepatocellular carcinoma
patients: univariate analysis.
Variable HR (95% CI) p
Cirrhosis Yes (n Z 70) 0.41 (0.1e1.8) 0.231
No (n Z 13) 1.0
Child-Pugh class B (n Z 20) 0.38 (0.1e2.6) 0.326
A (n Z 50) 1.0
Cool-down temperature (C)  70 (n Z 8) 0.98 (0.9e1.1) 0.722
> 70 (n Z 75) 1.0
Early termination No (n Z 64) 0.65 (0.1e3.2) 0.595
Yes (n Z 19) 1.0
Number of needle passes 2e3(n Z 62) 1.07 (0.6e1.8) 0.803
1 (n Z 21) 1.0
Size of index tumor  2 cm (n Z 78) 1.00 (0.5e2.0) 0.996
> 2 cm (n Z 23) 1.0
Patients with tumors in difficult-to-treat location Yes (n Z 24) 1.56 (0.78e3.84) 0.443
No (n Z 59) 1.0
CI Z confidence interval; HR Z hazard ratio.
RFA of HCC: Early versus standard termination 171weeks of RFA were significant in univariate analysis for
predicting local tumor progression, however, on multivar-
iate analysis only complete ablation after 4 weeks of RFA is
the independent predictive factor for local tumor progres-
sion (Table 3). The cumulative local tumor progression rate
of patients in the ET group was not significantly different to
those in the ST group (p Z 0.387, Figure 2). The 24 weeks
cumulative probability of local tumor progression was not
different among those with ET group [46.2%; 95% confi-
dence interval (CI) 0.191e0.733] and those with ST group
(25.6%; 95% CI 0.119e0.393).
Complications
All patients tolerated the procedure well. No major com-
plications occurred in both groups. Side effects seen were
not significant in both groups (pZ 0.612). One patient had
post-ablation syndrome (fever, general malaise) and oneTable 3 Factors predicting local recurrence on last follow-up b
Variable
Cirrhosis Yes (n Z 70)
No (n Z 13)
Child-Pugh class B (n Z 20)
A (n Z 50)
Tumor size  2 cm (n Z
> 2 cm (n Z
Patients with tumors in difficult-to-treat location Yes (n Z 24)
No (n Z 59)
Early termination No (n Z 64)
Yes (n Z 19)
Number of needle passes 2e3 (n Z 62)
1 (n Z 21)
Complete ablation of HCC after 4 w Yes (n Z 90)
No (n Z 11)
CI Z confidence interval; HCC Z hepatocellular carcinoma; HR Z hapatient had minimal asymptomatic perihepatic or renal
fluid for the ET group. Although five patients of the ST
group had asymptomatic pleural effusion, four had
asymptomatic pleural effusion plus ascites, two had post-
ablation syndrome, another two had minimal asymptomatic
perihepatic or renal fluid, and one had minimal pain. During
the follow-up period, no patients died but two patients
were lost to follow-up.Discussion
In this study, performing percutaneous RFA using the ET
technique is not different from the ST technique in terms of
achieving complete ablation. Local tumor progression and
side effects were also comparable between the groups. To
our knowledge, this study is the first of its kind in using such
a technique in performing RFA.y Cox proportional hazard model.
Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
0.32 (0.13e0.77) 0.011 0.56 (0.20e1.52) 0.251
1.0 1.0
0.4 6(0.17e1.29) 0.142
1.0
78) 0.75 (0.44e1.28) 0.285
23) 1.0
1.89 (0.94e3.18) 0.562
1.0
1.44 (0.62e3.32) 0.394
1.0
0.62 (0.36e1.09) 0.096
1.0
0.01 (0.01e0.11) < 0.001 0.04 (0.01e0.16) < 0.001
1.0 1.0
zard ratio.
Figure 2 Cumulative proportion of local recurrence among
patients with hepatocellular carcinoma treated with early
termination (ET) radiofrequency ablation versus standard
termination (ST). Cumulative local tumor progression rate of
those patients with hepatocellular carcinoma treated with ET
was not significantly different to those treated with ST of
radiofrequency ablation (pZ 0.387). n indicates the number of
remaining patients who were not lost to follow-up and still had
nonviable tumor.
172 Y.-T. Cheng et al.RFA has gained important role in ablation of small HCC
for its high rate of complete ablation and minimal inva-
siveness [4e11]. The determinants of complete ablation of
RFA include tumor factors including size, location,
conspicuousness, and heat sink effect, and ablation pro-
cedure factors including technical success and complica-
tions [12,13,20]. The technical success was also dependent
on the distribution of heat emission within the tumor [12].
To our knowledge, there is no universal ablation algorithm
for RFA procedure [20,23]. However, if the heat emission
was interrupted by the abnormally high temperature
related carbonization and charring tissue, the ablation ef-
fect and zone would be incomplete [20,24]. A manufacture
algorithm of radio-frequency was used an internal program
that automatically runs a 12-min pulsed energy ablation
cycle and adjusts the power output relative to tissue
impedance to optimize the diameter of ablated tissue
[3,4,12,13,16,18,20,23]. Nevertheless, frequent rising of
impedance between very short intervals was observed and
it subsequently might hinder heat further emission due to
more charring formation during frequent high impedance
[17,18,24,25]. Our finding in the current study showed a
similar rate of complications and local tumor progression
between standard and early termination of ablation pro-
cedures. The benefit of early termination may include
shorter ablation time, less discomfort, and probably moreuseful for ablation of larger tumor that requires overlapping
ablation.
Furthermore, to our knowledge, there is no definition of
early termination procedure. However, based on the
mechanism of radiofrequency emission, the power is
maintained at the setting level until tissue impedance rises
to 20 U above the baseline impedance [18]. The power
output is automatically reduced to zero for 15 seconds
(time of power temporary off) once the 20 U of threshold is
exceeded. The power is then returned to the initial peak
power setting until the tissue impedance rises again.
Therefore, if the power emission is < 15 seconds of power
temporary off, it may indicate that sufficient impedance
will interrupt further power emission, particularly, as the
ablation procedure is up to 9 minutes as compared with 12
minutes of standard ablation. Therefore, we defined the ET
group if a maximum power setting was done and if after 6
minutes the power emission was < 10 seconds for three
times per minute, the ablation was terminated after 9
minutes.
Although saline-linked RFA or using a novel needle
perfusion technique currently can reduce the charring ef-
fects and enhance efficacy [15,21,22,24,25], these devices
are slightly cumbersome and not so popular in most in-
stitutes. Therefore, the current algorithm using ET might
be an option to reduce charring effects and achieve com-
parable efficacy as the standard termination of RFA
procedures.
The limitation of this study is its small sample size.
Despite the small sample size, our study still showed that
ET of the ablation procedure would achieve comparable
complete ablation and local tumor progression compared
with ST of the RF procedure. Further randomized study or a
cohort study with larger sample size and longer follow-up
may be needed to confirm our findings.
In conclusion, using ET in RFA is as effective as the ST in
achieving complete ablation. It is also not associated with
an increased risk of local tumor progression, and side ef-
fects between the two groups are comparable.Conflicts of interest
All authors declared no conflicts of interest.References
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